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Variation in Cancer Risks, by Mutation Position, in BRCA2
Mutation Carriers
Deborah Thompson and Douglas Easton, on behalf of the Breast Cancer Linkage Consortium∗
Cancer occurrence in 164 families with breast/ovarian cancer and germline BRCA2 mutations was studied to
evaluate the evidence for genotype-phenotype correlations. Mutations in a central portion of the gene (the “ovarian
cancer cluster region” [OCCR]) were associated with a significantly higher ratio of cases of ovarian:breast cancer
in female carriers than were mutations 5′ or 3′ of this region ( ), extending previous observations. TheP ! .0001
optimal definition of the OCCR, as judged on the basis of deviance statistics, was bounded by nucleotides 3059–4075
and 6503–6629. The relative and absolute risks of breast and ovarian cancer associated with OCCR and non-
OCCR mutations were estimated by a conditional likelihood approach, conditioning on the set of mutations
observed in the families. OCCR mutations were associated both with a highly significantly lower risk of breast
cancer (relative risk [RR] 0.63; 95% confidence interval (95% CI) 0.46–0.84; ) and with a significantlyPp .0012
higher risk of ovarian cancer (RR p 1.88; 95% CI p 1.08–3.33; ). No other differences in breast orPp .026
ovarian cancer risk, by mutation position, were apparent. There was some evidence for a lower risk of prostate
cancer in carriers of an OCCR mutation (RRp 0.52; 95% CIp 0.24–1.00; ), but there was no evidencePp .05
of a difference in breast cancer risk in males. By age 80 years, the cumulative risk of breast cancer in male carriers
of a BRCA2 mutation was estimated as 6.92% (95% CIp 1.20%–38.57%). Possible mechanisms for the variation
in cancer risk are suggested by the coincidence of the OCCR with the RAD51-binding domain.
Introduction
Germline mutations in BRCA2 [MIM 600185] strongly
predispose to breast and ovarian cancer (Wooster et al.
1994, 1995; Tavtigian et al. 1996). BRCA2 mutations
also predispose to breast cancer in men (Wooster et al.
1994). There is evidence for an increased risk of several
other cancers—including prostate cancer, pancreatic
cancer, gall-bladder and bile-duct cancer, stomach can-
cer, and malignant melanoma—in carriers of BRCA2
(Breast Cancer Linkage Consortium 1999). Estimates of
the cumulative risk of breast cancer by age 70 years in
BRCA2 carriers vary from 37%, in a study based on
carriers of the 999del5 mutation in Iceland (Thorlacius
et al. 1998), to 84%, based on multiple-case families
collected through the Breast Cancer Linkage Consortium
(BCLC) (Ford et al. 1998). The ovarian cancer risk by
age 70 year has been estimated to be 20%–27% (Ford
et al. 1998; Breast Cancer Linkage Consortium 1999).
From the viewpoint of genetic counseling, it is im-
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portant to determine whether these variations in cancer
risk are associated with different mutations. In a pre-
vious study, based on 25 families with germline BRCA2
mutations, Gayther et al. (1997) reported that families
with a high proportion of ovarian cancers, relative to
the frequency of breast cancer, tended to have mutations
located within a 3.3-kb region in exon 11. They called
this region of BRCA2, bounded by nucleotides 3035
and 6629, the “ovarian cancer cluster region” (OCCR).
In an attempt to confirm and extend this observation,
we have analyzed a much larger data set, of 164 BRCA2
families. We have also attempted to estimate absolute
breast and ovarian cancer risks associated with muta-
tions in different regions of the gene, and we have ad-
ditionally been able to evaluate variations in the risks
of prostate cancer and of breast cancer in males.
Families and Methods
Families
The data set used in this study was based on the same
set of families previously used to evaluate risks, in
BRCA2 carriers, of cancers other than breast and ovar-
ian cancer (Breast Cancer Linkage Consortium 1999).
These families were collected by members of the BCLC
from 20 centers in western Europe, the United States,
and Canada (68 families from North America and 96
from Europe). Twenty-three of the families were ascer-
tained through systematic, population-based studies of
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patients with either breast cancer or ovarian cancer. The
remainder of the families were ascertained on the basis
of the presence of at least two relatives with either breast
cancer diagnosed at age !60 years or ovarian cancer at
any age, with more restrictive criteria being used by some
centers. Families were eligible for inclusion in this study
if at least one family member tested positive for a path-
ological BRCA2 mutation. Four families that, on the
basis of linkage evidence alone, had been included in the
previous analyses of this data set were excluded from
these analyses. We also excluded five families with pu-
tative missense mutations. These mutations would not
necessarily be expected, a priori, to have the same phe-
notypic effect as would be produced by protein-trun-
cating mutations at the same position in the gene, and
there were too few to allow them to be analyzed as a
separate group. With these exclusions, a total of 164
families with 92 distinct mutations were included in this
analysis. The 164 families include 25 used in the study
by Gayther et al. (1997), and herein are referred to as
the “CRC families”; details of these families have been
updated since that study.
Statistical Methods
To evaluate the evidence for a difference, in the breast:
ovarian cancer ratio, between OCCR and non-OCCR
mutations, we first computed the numbers of females
with breast cancer and the number of females with ovar-
ian cancer, over families with OCCR mutations and fam-
ilies with non-OCCR mutations, ignoring the second
cancer in an individual with bilateral breast cancer. The
resulting 2#2 contingency table was used to calculate
the deviance statistic, Dp 2S(observed)ln(observed/ex-
pected), asymptotically equivalent to Pearson’s x2 sta-
tistic. Counts were for cancers at any age, with only
tested noncarriers and known sporadic cases excluded.
Thirteen families were collected by the Montreal center
on the basis of the fact that they carry the Ashkenazi
6174delT mutation, but data on these families did not
contribute to this analysis. To overcome the problem
that the occurrence of breast/ovarian cancer in differ-
ent members of the same family are not independent,
the significance of the test statistic was estimated by
simulation. Within each center, families were randomly
permuted between the three types of mutation 10,000
times, and the resulting deviance statistics, calculated
under the null hypothesis of no genotype-phenotype re-
lation, were compared with that observed. The signifi-
cance level was calculated as the proportion of the ran-
dom deviance statistics that were as large as or larger
than that observed.
The definition of the OCCR was chosen by Gayther
et al. (1997) because of its good fit to the 25 CRC fam-
ilies. With the BCLC set of 164 families, including the
original CRC families, we were able to consider whether
this definition could be improved. For simplicity, we re-
stricted our candidate OCCRs to be single contiguous
regions of BRCA2. The deviance statistic for the 2#2
contingency table of number of breast cancers and num-
ber of ovarian cancers inside and outside the candidate
OCCR was computed, as described above, and was
maximized over the set of all possible candidate OCCRs.
This analysis was performed to find the optimal OCCR
definition for the CRC families, for the set of all non-
CRC families, and for all 164 families together.
Risks of breast and ovarian cancer associated with
mutations inside and outside the OCCR were estimated
by a maximum-likelihood approach. This approach al-
lows the disease information from untyped individuals
to be incorporated appropriately into the analysis. A full
likelihood would take the form
N
( )Lp P D ,C ,MFA ,l,b,f , j j j j
family j
where Dj is the vector of disease status of all females in
family j, Cj is the vector of carrier status of all individ-
uals, Mj is the mutation in the tested proband of family
j, and Aj is the ascertainment events for family j. Ascer-
tainment was assumed to depend on the first breast/
ovarian cancer in each woman and on the fact that the
proband must, by definition, be a carrier. Hence, the
information contained in vector Aj is a subset of the
information contained in Dj and Cj. l is the vector of
age-specific incidence rates of breast cancer and of ovar-
ian cancer in carriers of non-OCCR mutations, and b
is the log-RR (log value of the relative risk [RR]) to
carriers of OCCR mutations relative to carriers of non-
OCCR mutations, which is assumed to be constant with
age. f is a vector of the population frequencies of the
mutations. In practice, the population frequencies of
each specific mutation are unknown. We therefore based
inference on the likelihood conditional on the set of mu-
tations observed in each center, which is of the form
Ni
K ( ) L D ,CFM ,l,bj j j
jp1Lp  . (1)Ni
center i ( )  L AFM ,l,bj p(j)
p jp1
The sum in the denominator is over all permutations p
of mutations found in center i. Analyses were stratified
by center to allow for the possibility that ascertainment
criteria and mutation frequencies might vary between
centers. This will also take into account any mutation-
detection–sensitivity differences between centers. For
this purpose, the Montreal series of 13 Ashkenazi Jewish
families with the 6174delT mutation were considered to
be a single center. The parameters of interest related to
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the comparison of cancer risks associated with muta-
tions inside and outside the OCCR; hence, the specific
mutation Mj was replaced by an indicator variable tak-
ing values 1 and 0 for mutations inside and outside the
OCCR, respectively.
Breast cancer follow-up was censored at the date of
either prophylactic mastectomy or oophorectomy and at
the date of ovarian cancer diagnosis, because of potential
hormonal effects on breast cancer risk. Ovarian cancer
follow-up was censored at the date of prophylactic oo-
phorectomy, and both sets of follow-up were censored
at the earliest of date of death, 70th birthday, or 1 Jan-
uary 1996; that is, ovarian cancer follow-up subsequent
to either diagnosis of a breast cancer or mastectomy was
included in the analysis. The penetrance function was
constructed by use of a Poisson model for the number
of each type of cancer (0 or 1) diagnosed in each woman,
with the mean being dependent on carrier status. Among
carriers, the mutation-specific mean was parameterized
by use of the Cox model. The cancer rates assumed in
noncarriers were given separately for seven calendar pe-
riods during 1960–1996 and for 17 5-year age groups.
The rates were obtained from the series of publications
titled Cancer Incidence in Five Continents (Waterhouse
et al. 1976, 1982; Muir et al. 1987; Parkin et al. 1992,
1997) and from information provided by the Interna-
tional Agency for Research on Cancer. The likelihood
was maximized over the risk and log-RR parameters by
use of the program MENDEL (Lange et al. 1988). For
untested individuals, MENDEL estimates their carri-
er probability on the basis of both their phenotype and
the phenotype and carrier status of each of their rela-
tives; their contribution to the likelihood is weighted
accordingly. Maximum likelihoods were also found for
models with one or both of the log-RRs fixed at 0. The
maximum-likelihood estimates (MLEs) of the parame-
ters were used to compute the cumulative risks, by age,
of breast cancer and ovarian cancer, that are associated
with OCCR and non-OCCR mutations.
Among BRCA2 mutation carriers, the proportion of
cases of breast cancer at age t that have OCCR muta-
tions was estimated by use of Bayes’s theorem, as fol-
lows:
P(OCCRFbr(t),BRCA2)
P(br(t)FOCCR)P(OCCR)
p ,′ ′P(br(t)FOCCR)P(OCCR)P(br(t)FOCCR )P(OCCR )
where br(t) is the event of breast cancer diagnosed at
age t and P(br(t)FOCCR) and P(br(t)FOCCR′) are given
by the MLEs of the incidence rates. Equivalent calcu-
lations were made for ovarian cancer.
In addition to the elevated risks of breast/ovarian can-
cer in female carriers, BRCA2 mutations are also as-
sociated with increased risks of breast cancer and pros-
tate cancer in males. (We have previously reported that
BRCA2 mutations are also associated with increased
risks of pancreatic cancer, gallbladder and bile-duct can-
cer, stomach cancer, and malignant melanoma (Breast
Cancer Linkage Consortium 1999), but the small num-
bers of cases prohibits an extension of the genotype-
phenotype analysis to these cancer sites). The RRs of
male breast cancer and prostate cancer for carriers of
OCCR mutations relative to carriers of other BRCA2
mutations were estimated simultaneously, by use of the
conditional maximum-likelihood technique described
above. The likelihood maximized took a form similar
to that used in the estimation of the RR of breast/ovarian
cancer (eq. [1]). Disease information from females was
included, as for the likelihood of breast/ovarian cancer,
with parameters fixed at their MLEs. Males were cen-
sored at age 80 years, because of the higher average age
at diagnosis of these cancers. Ascertainment was deemed
to be independent of prostate cancer occurrence but was
deemed to depend on breast cancer occurrence in males.
MLEs of the risks and RRs were obtained, and the cu-
mulative risks were computed, as for the female carriers.
Results
Figure 1 shows the relative proportions of breast cancer
and ovarian cancer for each group of mutations, with
the original CRC families excluded. Consistent with the
results of Gayther et al. (1997), the OCCR mutations
are associated with the highest proportion of ovarian
cancers (23.8%, with the CRC families excluded), with
the regions 5′ and 3′ of the OCCR each having similar
proportions (8.8% and 9.6%, respectively). The devi-
ance statistic for testing the independence of mutation
position and cancer site is significant ( ;Dp 6.50 Pp
). The significance of this effect is considerably.027
strengthened when the original 25 CRC families are in-
cluded ( ; ).Dp 37.13 P ! .0001
When we maximized the deviance statistic over all
possible OCCR positions, the optimal OCCR definition
was nucleotides [3059–4075,6503–6629] inclusive (the
boundaries cannot be stated more precisely than this
because no mutations fall within these intervals). The
5′ boundary differed slightly from the original OCCR,
[3035,6629], but the change in deviance was small
(39.39 vs. 37.13). The change in definition would affect
only three families, and, since the difference in deviance
was slight, we chose to use the original definition in the
main analysis, rather than a new post hoc definition.
The odds ratios (ORs) for the region-by-region com-
parisons are shown in table 1. The most significant OR
is for the comparison of the OCCR with the non-OCCR
(ORp 3.86; ), suggesting either that ovarianP ! .0001
cancers are more common in families with OCCR mu-
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Table 1
OR for Breast:Ovarian Cancer, for
Comparison of Mutations in Different
Regions of BRCA2
Regions Compareda OR P
All families:
2 vs. 1 3.70 .0003
1 vs. 3 1.09 .54
2 vs. 3 4.02 .0001
OCCR vs. non-OCCR 3.86 !.0001
Families without CRC:
2 vs. 1 2.06 .023
1 vs. 3 .91 .40
2 vs. 3 1.88 .082
OCCR vs. non-OCCR 1.98 .023
a Region 1 is 5′ of OCCR, region 2 is the
OCCR, and region 3 is 3′ of OCCR.
Figure 1 Counts of breast cancer and ovarian cancer, by mutation location within BRCA2. Counts exclude tested noncarriers and other
known sporadic cases.
tations or that breast cancers are more common in fam-
ilies with non-OCCR mutations, or a combination of
the two effects. The effect is less strong when the CRC
families are excluded (the OR for the comparison of
OCCR vs. non-OCCR when only the 25 CRC families
are used is 108.7). The OR for the comparison of the
5′ and 3′ regions is not significantly different from unity.
Cancer risks for carriers of different mutations were
evaluated by maximization of the conditional likelihood
over the parameters (table 2). For the complete set of
164 families, the OCCR is associated with a signifi-
cantly reduced risk of breast cancer (RRp 0.63 [95%
CIp 0.46–0.84]; ) and with an increased riskPp .001
of ovarian cancer, although this effect is less statistically
significant (RR p 1.88 [95% CI p 1.08–3.33]; Pp
). Repeating the analysis with the CRC families.026
excluded weakens the breast cancer effect (RRp 0.68
[95% CI p 0.49–0.94]; ), whereas the RR ofPp .011
ovarian cancer ceases to be significant and actually
changes direction (RRp 0.85 [95% CIp 0.39–1.85];
). As predicted, replacing the original OCCRPp .2
boundaries with those given by maximizing the deviance
over all possible boundaries enhances both effects only
slightly (when all families are included, RR of breast
cancerp 0.59 [95% CIp 0.42–0.82] and RR of ovar-
ian cancer p 1.95 [95% CI p 1.05–3.63]).
Figure 2A shows the cumulative risks of breast cancer,
by age, for carriers of BRCA2 mutations inside and
outside the OCCR, and figure 2B shows the correspond-
ing cumulative risks of ovarian cancer. The cumulative
risk of breast cancer by age 70 years is 46.2% (95%
CI p 34.1%–60.3%) for non-OCCR mutations, com-
pared with 32.6% (95% CIp 23.2%–44.5%) for mu-
tations within the OCCR. The corresponding cumula-
tive risks of ovarian cancer by age 70 years are 10.9%
(95% CI p 5.5%–20.9%) for non-OCCR mutations
and 19.5% (95% CIp 11.6%–31.7%) for OCCR mu-
tations. When it is assumed that there is no relationship
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Table 2
MLEs of Age-Specific Incidence of Breast Cancer
and of Ovarian Cancer, for Non-OCCR Mutations,
and MLEs of OCCR:Non-OCCR RRs
Parameter MLE [95% CI]
Breast cancer:
!40 years .0027 [.001–.004]
40–49 years .0169 [.007–.026]
50–59 years .0196 [.006–.033]
60–69 years .0148 [.001–.028]
Ovarian cancer:
!40 years .0001 [.0–0.0004]
40–49 years .0010 [.0–.003]
50–59 years .0050 [.001–.009]
60–69 years .0051 [.0–.010]
RR:
Breast cancer .63 [.46–.84]
Ovarian cancer 1.88 [1.08–3.33 ]
between cancer risk and mutation location, the cumu-
lative risks by age 70 years are 40.6% (95% CI p
30.1%–53.3%) for breast cancer and 13.8% (95% CI
p 8.6%–21.8%) for ovarian cancer.
The corresponding estimates for males are shown in
table 3. The data set included 59 cases of breast cancer
in males and 72 cases of prostate cancer. Preliminary
estimations revealed that the OCCR:non-OCCR RR of
male breast cancer appeared to vary with age, where-
as the prostate RR remains approximately constant.
Therefore, the likelihood was modeled by use of a single
parameter for the log-RR of prostate cancer and two
separate parameters for the male breast cancer log-RR,
one at age !60 years and the other at age 60 years.
Overall, there was no evidence of a difference, by mu-
tation position, in male breast cancer risk: the OCCR
RR of male breast cancer was 11 at age !60 years and
!1 at age 60; however, both 95% CIs include 1. The
RR of prostate cancer, 0.52, achieved borderline sig-
nificance (95% CI p 0.24–1.00; ). The cu-Pp .05
mulative risk of prostate cancer by age 80 years was
estimated as 33.6% for non-OCCR mutations (95%
CIp 25.1%–44.1%) and 19.2% for OCCR mutations
(95% CI p 10.7%–33.1%). The estimated cumula-
tive risk of male breast cancer, estimated under the
model of no OCCR effect, was 2.8% (95% CI p
0.6%–13.0%) by age 70 years, rising to 6.9% by age
80 years (95% CI p 1.2%–38.6%).
Discussion
This report has described the evidence for genotype-phe-
notype correlations in 164 families with BRCA2 mu-
tations. After excluding the families originally reported
by Gayther et al. (1997), we found significant evidence
of a reduced breast:ovarian cancer–risk ratio in families
with mutations in the OCCR, thus confirming their ob-
servation. The limited number of families available to
Gayther et al. (1997) meant that they were unable to
separate the effects of mutation position on risk of breast
cancer versus its effect on risk of ovarian cancer. We
performed maximum-likelihood estimation of the RR
parameters for mutations in the OCCR relative to those
outside it , finding that, for mutations inside the OCCR,
the risk of breast cancer was 37% lower than that for
other BRCA2 mutations. We also found evidence of a
higher risk of ovarian cancer associated with OCCR
mutations, but this effect was less significant, and it was
not significant when the CRC families were excluded.
The stronger effect in the CRC families might be a re-
flection of their different pattern of ascertainment, since
they contain a high proportion of families that have
multiple cases of ovarian cancer but comparatively few
cases of breast cancer.
We also found a lower prostate cancer risk in the
OCCR, with the OCCR risk being 48% lower than the
non-OCCR risk. Perhaps surprisingly, we found no ev-
idence of variation in risk of male breast cancer, al-
though the comparatively small number of cases of this
disease gives the lowest power to detect any such dif-
ference. It is interesting that eight of nine families with
more than one case of male breast cancer have muta-
tions outside the OCCR.
The OCCR includes the 6174delT mutation, present
in ∼1% of the Ashkenazi Jewish population (Oddoux
et al. 1996) and seen in 23 families in our data set.
Thirteen of these families were ascertained in Montreal
on the basis of the fact that they carry the 6174delT
mutation, and, throughout the analysis, these families
were considered as a separate center. To assess whether
the observed effects could be explained entirely by this
mutation, the maximum-likelihood estimation was re-
peated without these 23 families. When this restricted
set is used, the OCCR-associated reduction in breast
cancer risk is weakened very slightly (RRp 0.67 [95%
CI p 0.48–0.93]; ), whereas the increase inPp .008
ovarian risk is identical in size but is less significant (RR
p 1.88 [95% CIp 1.05–3.40]; ). Hence, thePp .034
OCCR effect does not appear to be simply a conse-
quence of the Ashkenazi founder mutation. Recent stud-
ies of mutation frequencies in unselected Ashkenazi pa-
tients with either breast cancer or ovarian cancer suggest
that the 6174delT mutation is nearly four times as fre-
quent in patients with ovarian cancer as it is in patients
with breast cancer (Warner et al. 1999; Moslehi et al.
2000). This is in contrast to the Icelandic mutation
(999del5, 5′ of the OCCR), the frequency of which is
similar in patients with breast cancer and patients with
ovarian cancer, a finding that again is consistent with
the OCCR effect (Johannesdottir et al. 1996). In other,
nonfounder populations, our results suggest that ap-
proximately half of BRCA2 mutations in patients with
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Figure 2 Cumulative incidence, in BRCA2-mutation carriers, of breast cancer (A) and ovarian cancer (B), by mutation location
ovarian cancer would fall within the OCCR but that
only one quarter of those in patients with breast cancer
do so.
The distinctive phenotype associated with OCCR mu-
tations relative to other BRCA2 mutations appears to
be predominantly a reduced risk of breast cancer rather
than an increased risk of ovarian cancer. In view of these
data, the original term—“ovarian cancer cluster re-
gion”—appears to be something of a misnomer. How-
ever, most high-risk families are selected on the basis of
a certain number of cases of breast/ovarian cancer;
hence, the two cancer risks are somewhat hard to dis-
entangle (the correlation between the RR estimates was
.26). It may be that the ovarian cancer effect is actually
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Table 3
MLEs of Age-Specific Rates of Prostate Cancer
and of Male Cases of Breast Cancer, for Non-
OCCR Mutations, and MLEs of OCCR:Non-OCCR
RRs
Parameter MLE [95% CI]
Breast:
40-49 years .0003 [.0–.001]
50-59 years .0008 [.0–.003]
60-69 years .0016 [.0–.007]
70-79 years .0066 [.0–.036]
Prostate:
40-49 years .0003 [.0–.0001]
50-59 years .0043 [.002–.007]
60-69 years .0099 [.005–.015]
70-79 years .0265 [.014–.039]
RR:
Breast:
!60 years 1.73 [.52–5.78]
60 years .59 [.20–1.74]
Prostate .52 [.24–1.00]
stronger and that the breast cancer effect weaker, or
vice versa. A further potential complication is that the
risk of breast cancer and the risk of ovarian cancer are
likely to be correlated in families because of other shared
genetic or environmental factors. Although this does not
affect the evidence in favor of mutation-specific effects,
the precise estimates may need adjustment to incorpo-
rate other familial factors.
At present, we can only speculate about possible bi-
ological mechanisms that might be responsible for the
breast/ovarian cancer–risk variation that we have ob-
served. The function of BRCA2 remains unclear, partly
because its predicted amino acid sequence bears little
resemblance to proteins of known function (Wooster et
al. 1995; Tavtigian et al. 1996). The most significant
data suggest that BRCA2 is a nuclear protein that is
involved in DNA repair, via its association with the
double-strand DNA break-repair protein RAD51 (Ber-
twistle et al. 1997; Wong et al. 1997; Venkitaraman
2000). In vitro studies have shown that an interaction
between BRCA2 and RAD51 is mediated via a series
of eight amino acid repeats (i.e., BRC repeats) located
in a central region of the gene, as shown in figure 1
(Bork et al. 1996). The observation that at least six of
these RAD51-binding motifs lie within the boundaries
of the OCCR defined in this study suggests that they
may play a role in the variation in cancer risk we ob-
served. Furthermore, mice with homozygous truncating
BRCA2 mutations 5′ of the BRC repeats are embryonic
lethal, whereas mice in which at least three of the BRC
repeats are retained have only a partially lethal phe-
notype; some mice survive until birth but have stunted
growth and skeletal defects (e.g., see Connor et al. 1997;
Sharan et al. 1997; reviewed in Gayther and Ponder
1998). Although a C-terminus RAD51-binding site has
been reported in murine BRCA2, the most recent data
suggest that, in humans, the RAD51-BRCA2 interaction
takes place principally via the BRC repeats (Sharan et
al. 1997; Wong et al. 1997; Aihara et al. 1999; A. R.
Venkitaraman, personal communication).
Biological mechanisms that may explain these ge-
notype-phenotype variations rely on the assumption
that protein products of BRCA2 truncating mutations
retain partial or complete stability, although this has
not been demonstrated formally. One possibility is that
mutations occurring before the OCCR have no function
and are effectively null. Mutations occurring within the
OCCR would be predicted to retain one or more of the
BRC motifs and, presumably, some ability to bind with
RAD51 and the complex with which it is associated.
BRCA2 truncated by these mutations may have a partial
function or could behave in a dominant-negative man-
ner to negate the function of the RAD51-associated
complex. Truncated proteins occurring as a result of
mutations 3′ of the OCCR would be predicted to retain
all of the BRC repeats and may have a residual function
instead of behaving in a dominant-negative fashion. The
opposing effects that OCCR mutations have on the risk
of breast cancer and on the risk of ovarian cancer could
be explained if the DNA-repair pathways through
which BRCA2 acts differ between the two types of ep-
ithelial tissue. However, this theory is complicated by a
recent report that two nuclear-localization signals
(NLSs) located at the 3′ end of BRCA2 are essential for
its cellular localization (Spain et al. 1999). All mutations
in the present study are predicted to truncate BRCA2
5′ to the NLS, rendering it cytoplasmic and ruling out
any interaction with the RAD51 complex unless it is
transported into the nucleus by an alternative means,
such as homodimerization with wild-type BRCA2.
Another possible biological mechanism assumes the
existence of an in-frame alternative splicing of the
BRCA2 protein, a splicing that skips the OCCR, re-
sulting in a stable RNA isoform that retains some degree
of BRCA2 functionality; OCCR mutations would still
truncate the full-length protein but would have no effect
on the isoform, having been spliced out. If this isoform
were more frequent in breast epithelial tissue than in
ovarian epithelial tissue, then the partial rescue—and,
hence, the reduced penetrance—associated with OCCR
mutations would be evident only in breast cancer. At
least two stable RNA isoforms of BRCA1, each skipping
almost all of exon 11, have been found in breast epi-
thelial cells (Lu et al. 1996; Thakur et al. 1997; Wilson
et al. 1997). However, although an in-frame alternative
BRCA2 splicing that removes exon 12 has been dis-
covered, no isoform lacking exon 11 has been reported
(Bie`che and Lidereau 1999). More-detailed functional
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studies will be required to support or refute these
hypotheses.
Although the main aim of this study has been to assess
the variation, due to different mutations, in the risk of
breast cancer and in the risk of ovarian cancer, we were
also able to provide estimates of the absolute risks for
mutations within and outside the OCCR (33% and
46%, respectively, for breast cancer by age 70 years;
and 20% and 11%, respectively for ovarian cancer by
age 70 years). Estimation of the risk of breast cancer
employed only information about first breast cancers,
in contrast to the previous penetrance estimation per-
formed on essentially the same data set, which made
use only of information from second, contralateral
breast cancers (Breast Cancer Linkage Consortium
1999). The contralateral method gave higher breast can-
cer–risk estimates (52.3% [95% CI p 41.7%–61.0%]
by age 70 years), as would be expected. Both estimates
are lower than the 84% (95% CI p 43%–95%) re-
ported by Ford et al. (1998), who used a smaller number
of families with BRCA2 linkage information. Some of
this difference is likely to be due to chance, given the
wide confidence limits; however, selection of families
may also be a factor. The set of families in the present
study has been less strongly selected for family history
than were the linkage families reported in earlier studies.
It is possible that this would lead to a lower estimate
of absolute risk, as a result of other familial factors
being weaker. Also, Ford et al. (1998) estimated the risk
of ovarian cancer by age 70 years to be 27% (95% CI
p 0%–47%); this is considerably higher than the 14%
derived in the present study—although not inconsistent
with it, given the very wide 95% confidence interval for
the earlier estimate.
Although many studies have established male breast
cancer as a characteristic element of the BRCA2 phe-
notype (e.g., see Wooster et al. 1994; Tonin et al. 1995),
to date only one attempt has been made to estimate the
risk of breast cancer in male carriers of BRCA2 (Easton
et al. 1997). That study estimated that the cumulative
risk of breast cancer by age 70 years is 6.3% (95% CI
p 1.4%–25.6%), but this was based on just four cases
observed in two large BRCA2 pedigrees. Our estimated
cumulative risk of breast cancer by age 70 years, based
on 59 cases, is somewhat smaller (2.8%) and has a
narrower 95% CI (0.6%–13.0%). Our estimated risk
of breast cancer by age 80 years is 6.9% (95% CI p
1.2%–38.6%), equivalent to an RR of ∼80. If it is as-
sumed that the population frequency of BRCA2 mu-
tations is .0006 (Ford et al. 1995), this would imply
that ∼10% of male cases of breast cancer would be
expected to be due to BRCA2 mutations. The published
studies of BRCA2 prevalence in male cases of breast
cancer are consistent with an estimate of this order of
magnitude. In five studies of non-Icelandic populations,
the average prevalence is 13%, based on a total of 181
cases (Couch et al. 1996; Friedman et al. 1997; Mavraki
et al. 1997; Haraldsson et al. 1998; Csokay et al. 1999).
The higher prevalence, in Iceland, of BRCA2 mutations
among male patients with breast cancer (38% of 34
cases [Thorlacius et al. 1998]) is consistent with the high
frequency (∼1/200) of carriers of the 999del5 mutation
in the Icelandic population (Johannesdottir et al. 1996;
Thorlacius et al. 1997).
In conclusion, the present study confirms that mu-
tations in the OCCR of BRCA2 confer different risks
of breast, ovarian, and, possibly, prostate cancer than
are conferred by other mutations. At this stage, it seems
unlikely that the observed differences in risks are suf-
ficiently large to justify that clinical management should
differ according to the position of the mutation in a
family. Nevertheless, these differences should be borne
in mind when risk information is provided to mutation
carriers.
Appendix
Members of the Breast Cancer Linkage Consortium
The following are the contributing centers and the
names of the principal investigators (numbers in square
brackets are the number of families contributed by each
center):
CRC Genetic Epidemiology Unit (Cambridge) (coordinating center):
D. Easton, D. Thompson, and L. McGuffog
University of Aberdeen: N. Haites and A. Schofield [1]
Humangenetik, Kantonsspital (Basel): R. J. Scott [2] (present ad-
dress : University of Newcastle [Australia])
Departments of Medicine and Genetics, University of Washington
(Seattle): M.-C. King and E. Schubert [6]
Centre Jean Perrin, Clermont-Ferrand: Y. Bignon [1]
Institute of Cancer Research: M. Stratton, D. Ford, J. Peto, and R.
Eeles [19]
CRC Human Cancer Genetics Research Group: B. Ponder and S.
Gayther [11]
Deutsches Krebsforschungszentrum (Heidelberg) and University of
Wu¨rzburg: J. Chang-Claude, B. H. F. Weber, and U. Hamann [5]
Centro Nacional de Investigaciones Oncolo´gicas (Madrid): J. Benı´-
tez and A. Osorio [4]
University Central Hospital, Departments of Oncology and Obstet-
rics and Gynaecology (Helsinki): H. Eerola and H. Nevanlinna
[11]
Creighton University (Omaha) and International Agency for Re-
search on Cancer (Lyon): H. T. Lynch, S. Narod, D. Goldgar,
and G. Lenoir [8]
Institut Curie (Paris): D. Stoppa-Lyonnet and S. Gad [9]
University Hospital of Iceland (Reykjavik): A. Arason, R. B. Bar-
kardottir, and V. Egilsson [5]
Icelandic Cancer Society (Reykjavik): J. Eyfjord and H. Tulinius [5]
Imperial Cancer Research Fund (Leeds): D. T. Bishop [3]
University of Lund: A. Borg, N. Loman, O. Johannsson, and H.
Olsson [20]
McGill University (Montreal): P. Tonin and W. Foulkes [11]
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University of Montreal: P. Ghadirian, A. M. Mes-Masson, and D.
Provencher [8]
University of Pennsylvania: B. Weber [11]
University of Leiden and Foundation for the Detection of Heredi-
tary Tumours (Leiden) and Erasmus Medical Center and Daniel
den Hoed Cancer Center (Rotterdam) P. Devilee, H. Vasen, C. J.
Cornelisse, H. Meijers-Heijboer, and J. G. M. Klijn [8]
University of Toronto: S. Narod, J.-S. Brunet, and R. Moslehi [19]
University of Utah: S. L. Neuhausen and L. Cannon-Albright [6]
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